Unicycive Therapeutics (UNCY) Earnings Date, Estimates & Call Transcripts $4.20 -0.05 (-1.18%) Closing price 08/22/2025 04:00 PM EasternExtended Trading$4.23 +0.03 (+0.62%) As of 08/22/2025 07:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Earnings Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock Unicycive Therapeutics Earnings Summary Unicycive Therapeutics posted Q2 2025 earnings on August 14, 2025, reporting an EPS of -$0.52, which topped the consensus estimate of -$0.70 by $0.18. With a trailing EPS of -$4.12, Unicycive Therapeutics' earnings are expected to grow next year, from ($0.23) to ($0.08) per share. Q2 2025 Earnings ResourcesQ2 2025 Earnings ReportLatest Q2 2025 Earnings DateAug. 14EstimatedConsensus EPS (Aug. 14) -$0.70 Actual EPS (Aug. 14) -$0.52 Beat By $0.18 Get Unicycive Therapeutics Earnings Alerts Want to stay updated on the latest earnings announcements and upcoming reports? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Unicycive Therapeutics and other key companies, straight to your inbox. Enter your email to sign up for newsletter Sign Up Skip Charts & View Estimated and Actual Earnings DataUNCY Earnings Estimates and Actuals by QuarterEarnings Estimates and Acutals by Quarter Chart DescriptionThe chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.UNCY Estimated and Actual Revenue by QuarterEstimated Revenue and Actual Revenue by Quarter Chart DescriptionThe chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter. Unicycive Therapeutics Analyst EPS EstimatesQuarterNumber of EstimatesLow EstimateHigh EstimateAverage EstimateQ1 20253-$3.00-$0.80-$1.77Q2 20253-$1.10-$0.70-$0.87Q3 20253-$0.90-$0.50-$0.63Q4 20253-$0.60$1.30$0.13 FY 2025 12 -$5.60 -$0.70 -$3.13 Q1 20261$2.70$2.70$2.70Q2 20261$2.90$2.90$2.90Q3 20261$3.70$3.70$3.70Q4 20261$4.70$4.70$4.70 Unicycive Therapeutics Earnings History by Quarter Custom Range 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 5 Years 10 Years Time Frame Start Date End Date Export to Excel DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueDetails8/14/2025Q2 2025-$0.70-$0.52+$0.18-$0.52--5/14/2025Q1 2025-$1.40-$0.50+$0.90-$0.05--3/27/2025Q4 2024-$1.30-$2.60 -$1.30-$0.26--8/14/2024Q2 2024-$2.30-$1.50+$0.80-$0.15--5/13/2024Q1 2024-$1.80-$2.70 -$0.90$0.07--3/28/2024Q4 2023-$1.80-$1.60+$0.20-$0.16--11/14/2023Q3 2023-$1.30-$1.30--$0.13-- Unicycive Therapeutics Earnings - Frequently Asked Questions When did Unicycive Therapeutics announce their last quarterly earnings? Unicycive Therapeutics (NASDAQ:UNCY) last announced its quarterly earning data on Thursday, August 14, 2025. Learn more on UNCY's earnings history. Did Unicycive Therapeutics beat their earnings estimates last quarter? In the previous quarter, Unicycive Therapeutics (NASDAQ:UNCY) reported ($0.52) earnings per share (EPS) to beat the analysts' consensus estimate of ($0.70) by $0.18. Learn more on analysts' earnings estimate vs. UNCY's actual earnings. How much revenue does Unicycive Therapeutics generate each year? Unicycive Therapeutics (NASDAQ:UNCY) has a recorded annual revenue of $680,000.00. How much profit does Unicycive Therapeutics generate each year? Unicycive Therapeutics (NASDAQ:UNCY) has a recorded net income of -$36.73 million. UNCY has generated -$4.12 earnings per share over the last four quarters. What is Unicycive Therapeutics' EPS forecast for next year? Unicycive Therapeutics' earnings are expected to grow from ($0.23) per share to ($0.08) per share in the next year. More Earnings Resources from MarketBeat Related Companies Sagimet Biosciences Earnings Date SOPHiA GENETICS Earnings Date Aardvark Therapeutics Earnings Date Adherex Technologies Earnings Date Galectin Therapeutics Earnings Date Alector Earnings Date Tvardi Therapeutics Earnings Date Monopar Therapeutics Earnings Date CARGO Therapeutics Earnings Date ProQR Therapeutics Earnings Date Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles After Earnings Miss, Walmart Is Still a Top Consumer Staples PlayRoyal Caribbean Earnings Beat Fuels Strong 2025 OutlookDLocal Stock Soars 43% After Earnings Beat and Raised GuidanceGreen Dot's 30% Rally: Turnaround Takes Off on Explosive EarningsElbit Systems Jumps on Record Earnings and a $1.6B ContractBrinker Serves Up Earnings Beat, Sidesteps Cost PressuresWhy BigBear.ai Stock's Dip on Earnings Can Be an Opportunity This page (NASDAQ:UNCY) was last updated on 8/23/2025 by MarketBeat.com Staff From Our PartnersBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Unicycive Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Unicycive Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access